SCHEMBL19784196

SCHEMBL19784196

O=C(N[C@H](C1CC1)C(F)(F)F)c1cn(-c2ncc(F)cc2F)c2nc(N3CC4CC4(O)C3)ccc2c1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.33
ULK1 O75385 1/20 0.33
ULK2 Q8IYT8 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
STK17A Q9UEE5 1/20 0.33
EPHA2 P29317 1/20 0.33
FLT4 P35916 1/20 0.33
GSK3B P49841 1/20 0.33
RARB P10826 1/20 0.33
TBXAS1 P24557 1/20 0.33
SLC6A3 Q01959 1/20 0.33
SLC22A2 O15244 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
XBP1 P17861 1/20 0.32
NFKB1 P19838 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22590995 1.00 KMT2A (0.33) KMT2AULK1ULK2MKNK2STK17A
SCHEMBL19784058 1.00 KMT2A (0.33) KMT2AULK1ULK2MKNK2STK17A
SCHEMBL21220075 0.93 ULK1 (0.32) ULK1ULK2MKNK2STK17ASLC22A2
SCHEMBL19784061 0.93 ULK1 (0.32) ULK1ULK2MKNK2STK17ASLC22A2
SCHEMBL22590969 0.93 ULK1 (0.32) ULK1ULK2MKNK2STK17ASLC22A2
SCHEMBL19784062 0.92 EPHA2 (0.34) KMT2AEPHA2FLT4GSK3BRARB
SCHEMBL20531841 0.90 SLC22A2 (0.32) KMT2AULK1ULK2MKNK2STK17A
SCHEMBL18313354 0.90 SLC22A2 (0.32) KMT2AULK1ULK2MKNK2STK17A
SCHEMBL21237916 0.90 PDE4A (0.34) JAK2
SCHEMBL21220074 0.90 PDE4A (0.34) JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3481823-B1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF Bayer Pharma AG (DE) 2020-10-28 EP claimed
EP-3481823-B1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF Bayer Pharma AG (DE) 2020-10-28 EP disclosed
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-08 US disclosed
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-08 US disclosed
WO-2018011017-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241562-A1 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF GLS, TNNI3, AADAC KMT2A 3602/4885ULK1 2161/4885ULK2 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.